Samsung Bioepis Aims To Compete On Higher-Strength Humira In US
FDA Accepts sBLA For 100mg/ml Citrate-Free Version Of Hadlima Biosimilar
• By David Wallace
Samsung Bioepis is targeting high-concentration adalimumab • Source: igor kisselev / Alamy Stock Vector 
